FIELD: medicine.
SUBSTANCE: ophthalmological means contains the following components, wt %: sodium chloride 0.8-0.9, tris-(hydroxymethyl)-methylamine 0.08-0.12, nipagine 0.0075-0.0125, trilon B 0.005-0.01, riboflavin-mononucleotide 0.09-0.11, hydroxypropyl methylcellulose 0.9-1.1 and distilled purified water to 100.
EFFECT: application of the invention does not reduce the thickness of the cornea, ensures corneal stroma saturation with riboflavin without the use of devices for cornea iontophoresis, allows to conduct the procedure in patients with a corneal thickness of about 400 μm, saving the active substance of the ophthalmic agent.
1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HYPOSMOTIC OPHTHALMIC MEANS FOR ULTRAVIOLET CROSSLINKING OF THIN CORNEAS | 2016 |
|
RU2631604C1 |
| OPHTHALMIC AGENT FOR TRANSEPITHELIAL ULTRAVIOLET CORNEAL COLLAGEN CROSSLINKING | 2014 |
|
RU2560669C1 |
| OPHTHALMIC CROSS-LINKING AGENT-2 | 2012 |
|
RU2475248C1 |
| CROSS-LINKING OPHTHALMIC AGENT | 2009 |
|
RU2412707C1 |
| METHOD OF TREATMENT OF KERATECTASIA BY THE METHOD OF PULSE ACCELERATED ULTRAVIOLET CROSSLINKING OF CORNEA | 2017 |
|
RU2682494C1 |
| COMBINED METHOD FOR THE TREATMENT OF CORNEAL DISEASES WITH THE USE OF KERATOPLASTY AND CROSS-LINKING | 2017 |
|
RU2676434C1 |
| METHOD OF CORNEAL GRAFT PREPARATION FOR LAYER-BY-LAYER KERATOPLASTY | 2019 |
|
RU2723135C1 |
| METHOD OF TREATING EPITHELIAL-ENDOTHELIAL CORNEAL DYSTROPHY | 2019 |
|
RU2703361C1 |
| OPHTHALMOLOGICAL MEANS FOR CORNEAL INJURIES AND DISEASES DIAGNOSTICS | 2016 |
|
RU2633083C1 |
| METHOD OF TREATING HERPETIC KERATITIS | 2013 |
|
RU2531426C1 |
